To develop effective disease-modifying therapies for neurodegenerative diseases, reliable
markers of diagnosis, disease activity and progression are a research priority. The fact that …

Filamentous protein inclusions in neurons (Lewy bodies, LB) and dystrophic neurites
containing pathologic α-synuclein (αSyn) are the morphologic hallmarks of sporadic …

The present study demonstrates that blood samples can be used as a source of miRNA
identification associated to Parkinson's disease (PD). A set of six differentially expressed …

Abstract α-Synuclein is a major component of Lewy bodies and glial cytoplasmic inclusions,
pathological hallmarks of idiopathic Parkinson's disease and multiple system atrophy, and it …

Parkinson disease (PD) is the second most common neurodegenerative disease after
Alzheimer disease. Although PD has a relatively narrow clinical phenotype, it has become …

Objective: The aims of the present study were to profile the expression of several candidate
microRNAs (miRNAs) in blood from l-dopa-treated and drug-naive patients with Parkinson …

The pathogenesis of Alzheimer's disease (AD) and the commonest cause of dementia in the
elderly remain incompletely understood. Recently, epigenetic modifications have been …

Parkinson's disease (PD) is a degenerative disease that can cause motor, cognitive, and
behavioral disorders. The treatment strategies being developed are based on the typical …

This study demonstrates that in vitro incubation of isolated rat brain mitochondria with
recombinant human α-synuclein leads to dose-dependent loss of mitochondrial …

Glial cell line-derived neurotrophic factor (GDNF) and Neurturin (NRTN) bind to a receptor
complex consisting of a member of the GDNF family receptor (GFR)-α and the Ret tyrosine …